Mayo Clinic participated in the landmark clinical trial that led to the FDA approval of Yescarta CAR-T therapy—and now Mayo Clinic is one of the first cancer centers certified to provide treatment.
The Mayo Clinic CAR T-Cell Therapy Program offers a new cancer immunotherapy for people with aggressive B-cell non-Hodgkin's lymphoma. The treatment, chimeric antigen receptor (CAR) T-cell therapy, was approved October 2017 by the Food and Drug Administration for certain types of lymphoma.
The program expands Mayo Clinic's treatment options for people with aggressive B-cell non-Hodgkin's lymphoma. If you are eligible and scheduled for this treatment, you'll go through a process that takes, on average, seven weeks — part of it in a hospital at Mayo Clinic's campus in Rochester, Minnesota, and part of it on an outpatient basis.
The Mayo Clinic CAR T-Cell Therapy Program is one of a very few such programs at select medical centers with experts trained and certified to manage CAR T-cell therapy. Mayo Clinic was one of the centers that treated people in the landmark clinical trial that led to FDA approval of this therapy in lymphoma.
Yi Lin, M.D., a Mayo Clinic hematologist and the chair of the cellular therapeutic cross-disciplinary group at the CAR T-Cell Therapy Program, says she is excited about the potential of CAR T.
“This is really the first treatment of its kind that is coming to the market,” Dr. Lin says.
"Mayo Clinic has a long history of dedication to provide the best care possible for patients receiving complex treatments. CAR T therapy is the next era of new, complex but exciting cancer treatment that we will excel at and provide for our patients.”
Liked by Lisa Lucier, Connect Moderator
Send an email to invite people you know to join the Hematology page.